There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
<p class="first" id="d3865163e83">Nearly one-third of patients with rheumatoid arthritis
(RA) do not respond to Methotrexate
(MTX), the first-line therapy in RA. CD39, an ectonucleotidase highly expressed on
regulatory T cells (Tregs), is responsible for production of adenosine, an important
anti-inflammatory mediator of MTX action. Higher expression of CD39 on Tregs improves
their suppressive capacity. Therefore, we aimed to study the role of CD39+ Treg frequency
as a biomarker for MTX treatment response in RA.
</p>